Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Anguille, Sébastien ^a,b   Lion, Eva ^a   Tel, Jurjen ^c   de Vries, I Jolanda M ^c   Couderé, Karen ^a   Fromm, Phillip D ^d   van Tendeloo, Viggo F ^a   Smits, Evelien L ^a,b   Berneman, Zwi N ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ANZAC RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; GRANZYME B; INTERLEUKIN 15; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; IMMUNOTHERAPY; MOUSE; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; UPREGULATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD56; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; GRANZYMES; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; MONOCYTES; MYELOID CELLS; NEOPLASMS;

EID: 84871699575     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051851     Document Type: Article

References (64)

1. Lanier LL, Testi R, Bindl J, Phillips JH, (1989) Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 169: 2233-2238.
2. Spits H, Lanier LL, (2007) Natural killer or dendritic: what's in a name? Immunity 26: 11-16.
3. Hanna J, Gonen-Gross T, Fitchett J, Rowe T, Daniels M, et al. (2004) Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest 114: 1612-1623.
4. Pillarisetty VG, Katz SC, Bleier JI, Shah AB, Dematteo RP, (2005) Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. J Immunol 174: 2612-2618.
5. Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, et al. (2006) Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 12: 207-213.
6. Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, et al. (2006) A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12: 214-219.
7. Blasius AL, Barchet W, Cella M, Colonna M, (2007) Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med 204: 2561-2568.
8. Vosshenrich CA, Lesjean-Pottier S, Hasan M, Richard-Le Goff O, Corcuff E, et al. (2007) CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med 204: 2569-2578.
9. Caminschi I, Ahmet F, Heger K, Brady J, Nutt SL, et al. (2007) Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J Exp Med 204: 2579-2590.
10. Wesa AK, Storkus WJ, (2008) Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ 15: 51-57.
11. Chauvin C, Josien R, (2008) Dendritic cells as killers: Mechanistic aspects and potential roles. J Immunol 181: 11-16.
12. Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E, (2010) Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother 59: 1-11.
13. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, et al. (2012) Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 122: 575-585.
14. Chan CW, Housseau F, (2008) The 'kiss of death' by dendritic cells to cancer cells. Cell Death Differ 15: 58-69.
15. Anguille S, Van Tendeloo V, Berneman Z, (2012) Dendritic cell-based therapeutic vaccination for acute myeloid leukemia. Bull Cancer 99: 635-642.
16. Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN, (2012) Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 14: 647-656.
17. Anguille S, Smits ELJM, Cools N, Goossens H, Berneman ZN, et al. (2009) Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 7: 109.
18. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, et al. (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27: 3135-3142.
19. Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VF, (2011) Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin 7: 579-584.
20. Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF, (2009) Dendritic cell-based cancer gene therapy. Hum Gene Ther 20: 1106-1118.
21. Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, et al. (2001) Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 194: 1013-1020.
22. Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, et al. (2007) IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol 37: 1678-1690.
23. Harris KM, (2011) Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J Leukoc Biol 90: 727-734.
24. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, et al. (2012) Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 18: 807-815.
25. Lion E, Anguille S, Berneman ZN, Smits EL, Van Tendeloo VF, (2011) Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One 6: e20952.
26. Milush JM, Long BR, Snyder-Cappione JE, Cappione AJ, York VA, et al. (2009) Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood 114: 4823-4831.
27. Walzer T, Jaeger S, Chaix J, Vivier E, (2007) Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol 19: 365-372.
28. Lanier LL, Chang C, Phillips JH, (1994) Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 153: 2417-2428.
29. Steinman RM, Nussenzweig MC, (1980) Dendritic cells: features and functions. Immunol Rev 53: 127-147.
30. Anguille S, Van Tendeloo VF, Berneman ZN, (2012) Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 26: 2186-2196.
31. Welte S, Kuttruff S, Waldhauer I, Steinle A, (2006) Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol 7: 1334-1342.
32. Palucka K, Banchereau J, (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12: 265-277.
33. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ, (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10: 475-480.
34. Farag SS, Caligiuri MA, (2006) Human natural killer cell development and biology. Blood Rev 20: 123-137.
35. Bigley V, Spence LE, Collin M, (2010) Connecting the dots: monocyte/DC and NK subsets in human peripheral blood. Blood 116: 2859-2860.
36. Robertson MJ, Caligiuri MA, Manley TJ, Levine H, Ritz J, (1990) Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol 145: 3194-3201.
37. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P, (2000) Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 164: 1148-1152.
38. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, et al. (2001) Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clin Cancer Res 7: 804s-810s.
39. Cookson S, Reen D, (2003) IL-15 drives neonatal T cells to acquire CD56 and become activated effector cells. Blood 102: 2195-2197.
40. Kelly-Rogers J, Madrigal-Estebas L, O'Connor T, Doherty DG, (2006) Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol 67: 863-873.
41. Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, et al. (2008) Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 14: 4232-4240.
42. Urban EM, Li H, Armstrong C, Focaccetti C, Cairo C, et al. (2009) Control of CD56 expression and tumor cell cytotoxicity in human Vgamma2Vdelta2 T cells. BMC Immunol 10: 50.
43. Correia MP, Costa AV, Uhrberg M, Cardoso EM, Arosa FA, (2011) IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology 216: 604-612.
44. Fanger NA, Maliszewski CR, (1999) Schooley K, Griffith TS (1999) Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190: 1155-1164.
45. Schmitz M, Zhao S, Deuse Y, Schakel K, Wehner R, et al. (2005) Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol 174: 4127-4134.
46. Papewalis C, Jacobs B, Wuttke M, Ullrich E, Baehring T, et al. (2008) IFN-alpha skews monocytes into CD56(+)-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol 180: 1462-1470.
47. Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, et al. (2011) Interferon-alpha in acute myeloid leukemia: an old drug revisited. Leukemia 25: 739-748.
48. Kalb ML, Glaser A, Stary G, Koszik F, Stingl G, (2012) TRAIL+ human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J Immunol 188: 1583-1591.
49. Lacasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, et al. (2011) Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-gamma-dependent mechanism. J Immunol 187: 6310-6317.
50. Chapoval AI, Tamada K, Chen L, (2000) In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood 95: 2346-2351.
51. Vidalain PO, Azocar O, Yagita H, Rabourdin-Combe C, Servet-Delprat C, (2001) Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. J Immunol 167: 3765-3772.
52. Manna PP, Mohanakumar T, (2002) Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J Leukoc Biol 72: 312-320.
53. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, et al. (2007) Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 204: 1441-1451.
54. Manna PP, Hira SK, Das AA, Bandyopadhyay S, Gupta KK, (2012) IL-15 activated human peripheral blood dendritic cell kill allogeneic and xenogeneic endothelial cells via apoptosis. Cytokine 61: 118-126.
55. Matsui T, Connolly JE, Michnevitz M, Chaussabel D, Yu CI, et al. (2009) CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 182: 6815-6823.
56. Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, et al. (2012) A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother 35: 54-65.
57. Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, et al. (2012) Human plasmacytoid dendritic cells are equipped with antigen presenting- and tumoricidal-capacities. Blood 120: 3936-3944.
58. Luckey U, Maurer M, Schmidt T, Lorenz N, Seebach B, et al. (2011) T cell killing by tolerogenic dendritic cells protects mice from allergy. J Clin Invest 121: 3860-3871.
59. Suss G, Shortman K, (1996) A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 183: 1789-1796.
60. Barblu L, Machmach K, Gras C, Delfraissy JF, Boufassa F, et al. (2012) Plasmacytoid dendritic cells from HIV controllers produce IFN-alpha and differentiate into functional killer pDC under HIV activation. J Infect Dis 206: 790-801.
61. Choy JC, Hung VH, Hunter AL, Cheung PK, Motyka B, et al. (2004) Granzyme B induces smooth muscle cell apoptosis in the absence of perforin: involvement of extracellular matrix degradation. Arterioscler Thromb Vasc Biol 24: 2245-2250.
62. Pardo J, Wallich R, Ebnet K, Iden S, Zentgraf H, et al. (2007) Granzyme B is expressed in mouse mast cells in vivo and in vitro and causes delayed cell death independent of perforin. Cell Death Differ 14: 1768-1779.
63. Pipkin ME, Lieberman J, (2007) Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol 19: 301-308.
64. Thiery J, Keefe D, Boulant S, Boucrot E, Walch M, et al. (2011) Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nat Immunol 12: 770-777.